Live Breaking News & Updates on Corvus pharmaceuticals

Stay informed with the latest breaking news from Corvus pharmaceuticals on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Corvus pharmaceuticals and stay connected to the pulse of your community

Towerview LLC Acquires 94,395 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Towerview LLC boosted its holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report) by 27.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 436,873 shares of the company’s stock after purchasing an additional 94,395 shares during the period. Corvus Pharmaceuticals accounts for approximately 0.5% of Towerview LLC’s portfolio, making the stock its 17th […]

Cantor-fitzgerald , Nasdaq , Vanguard-group-inc , Renaissance-technologies , Quarter-for-corvus-pharmaceuticals , Corvus-pharmaceuticals-inc , Corvus-pharmaceuticals-stock-performance , Blackrock-inc , Corvus-pharmaceuticals-profile , News-ratings-for-corvus-pharmaceuticals-daily , Corvus-pharmaceuticals

Towerview LLC Boosts Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Towerview LLC grew its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report) by 27.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 436,873 shares of the company’s stock after buying an additional 94,395 shares during the quarter. […]

United-states , American , Tower-research-capital , Corvus-pharmaceuticals-inc , Renaissance-technologies , Cantor-fitzgerald , Exchange-commission , Corvus-pharmaceuticals , News-ratings-for-corvus-pharmaceuticals-daily , American-century-companies-inc , Corvus-pharmaceuticals-stock-performance

Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc. announced the initiation of the Company?s randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe...

United-states , Corvus-pharmaceuticals-inc , Corvus-pharmaceuticals , Soquelitinib-atopic-dermatitis-phase , Trial-the , Eczema-area , Severity-index , Investigator-global-assessment ,

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitorCorvus...

United-states , Leiv-lea , Richarda-miller , Sheryl-seapy , Corvus-pharmaceuticals , Nasdaq , Exchange-commission , Company-annual-report-on-form , Company-phase , Corvus-pharmaceuticals-inc , Soquelitinib-atopic-dermatitis-phase , Eczema-area

Corvus Pharmaceuticals, Inc. to Post FY2024 Earnings of ($0.35) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report) – Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($0.35) per share for the year, up from their prior estimate of […]

News-ratings-for-corvus-pharmaceuticals-daily , Cantor-fitzgerald , Corvus-pharmaceuticals , Corvus-pharmaceuticals-stock-performance , Nasdaq , Tucker-asset-management , Corvus-pharmaceuticals-inc , Acadian-asset-management , Institutional-trading-of-corvus-pharmaceuticals , Free-report , Corvus-pharmaceutical

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Update

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,490,000 shares, an increase of 17.3% from the February 29th total of 1,270,000 shares. Based on an average daily trading volume, of 218,100 […]

Corvus-pharmaceuticals-stock-performance , Tucker-asset-management , Corvus-pharmaceuticals-inc , Cantor-fitzgerald , Nasdaq , Renaissance-technologies , News-ratings-for-corvus-pharmaceuticals-daily , Corvus-pharmaceuticals-company-profile , Corvus-pharmaceuticals , Institutional-trading-of-corvus-pharmaceuticals , Tower-research-capital

Stock Analysts' Updated EPS Estimates for April 1st (ACHV, ACRV, ADSK, ADTH, AFG, AFMD, AGO, AGS, AIG, ALKS)

Stock Analysts' Updated EPS Estimates for April 1st (ACHV, ACRV, ADSK, ADTH, AFG, AFMD, AGO, AGS, AIG, ALKS)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Canada , Essex , Ohio , United-states , California , Cincinnati , America , American , Eli-lilly , Novo-nordisk , Stifel-nicolaus , Ascendis-pharma

Mizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)

Mizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Nasdaq , Vanguard-group-inc , Tucker-asset-management , Corvus-pharmaceuticals-company-profile , Corvus-pharmaceuticals-trading , Corvus-pharmaceuticals , Corvus-pharmaceuticals-inc , American-century-companies-inc , News-ratings-for-corvus-pharmaceuticals-daily

Investment Analysts' Updated EPS Estimates for March 27th (ADBE, APLS, BABA, CHKP, CLSK, CMCX, CRVS, DPLM, ECOR, ENV)

Investment Analysts’ updated eps estimates for Wednesday, March 27th: Adobe (NASDAQ:ADBE) had its buy rating reaffirmed by analysts at Mizuho. The firm currently has a $680.00 price target on the stock. Apellis Pharmaceuticals (NASDAQ:APLS) had its neutral rating reiterated by analysts at Mizuho. Mizuho currently has a $60.00 target price on the stock. Alibaba Group […]

Canada , William-blair , Adobe-inc , News-ratings-for-adobe-inc-daily , Royal-bank , Strix-group , Vanquis-banking-group , Vermilion-energy , Corvus-pharmaceuticals , Alibaba-group , Pharos-energy , Check-point-software-technologies

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

While-corvus-pharmaceuticals , Corvus-pharmaceuticals-to-raise-more-cash , Corvus-pharmaceuticals , Corvus-pharmaceutical ,